lutetium (177 Lu) chloride

This medicine is authorised for use in the European Union.


EndolucinBeta contains the radioactive compound lutetium (177Lu) chloride and is used for radiolabelling other medicines. Radiolabelling is a technique for tagging (or labelling) medicines with radioactive compounds so they can carry radioactivity to where it is needed in the body, for example the site of a tumour.

EndolucinBeta isl to be used to radiolabel medicines that have been specifically developed for use with lutetium (177Lu) chloride.

This EPAR was last updated on 28/09/2020

Authorisation details

Product details
Agency product number
Active substance
lutetium (177 Lu) chloride
International non-proprietary name (INN) or common name
lutetium (177 Lu) chloride
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
ITM Medical Isotopes GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Lichtenbergstrasse 1, Garching b.
Muenchen, Bayern, 85748

Product information

24/09/2020 EndolucinBeta - EMEA/H/C/003999 - PSUSA/00010391/201912


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Therapeutic radiopharmaceuticals

Therapeutic indication

EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating